Progyny will announce its Q4 and annual financial results on February 26, 2026, followed by a conference call.
Quiver AI Summary
Progyny, Inc. will release its financial results for the fourth quarter and full year ending December 31, 2025, on February 26, 2026, after market close. A conference call to discuss these results will take place at 4:45 p.m. Eastern Time, with details for both U.S. and international participants to join provided in the announcement. An audio replay of the call will be available until March 5, 2026, and can also be accessed online. Progyny is a leading company in women's health and family building solutions, known for its comprehensive services that support patients and healthcare providers while reducing costs. Based in New York City, Progyny has received several accolades for its impact and growth in the healthcare industry.
Potential Positives
- Progyny is positioned as a global leader in women's health and family building solutions, highlighting its importance in a significant and growing sector.
- The upcoming financial results announcement and conference call suggest strong corporate transparency and engagement with stakeholders.
- Progyny’s recognition by various prestigious organizations underscores its reputation and credibility within the industry.
- The company's comprehensive benefits solution is designed to optimize clinical outcomes and reduce healthcare costs, which may attract more employers and clients.
Potential Negatives
- None
FAQ
When will Progyny release its financial results for 2025?
Progyny will report its financial results on February 26, 2026, after market close.
How can I join the Progyny conference call?
Participants in the U.S. can dial 1.866.825.7331 with passcode 265484 to join the call.
Is there an option to replay the conference call?
Yes, an audio replay will be available until March 5, 2026, using 1.800.332.6854 (U.S.) or 1.973.528.0005 (international).
Where can I find more information about Progyny?
Additional information can be found on Progyny's website at www.progyny.com.
What recognition has Progyny received?
Progyny has been recognized by TIME100, CNBC Disruptor 50, and Forbes' Best Employers, among others.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PGNY Insider Trading Activity
$PGNY insiders have traded $PGNY stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $PGNY stock by insiders over the last 6 months:
- PETER ANEVSKI (CHIEF EXECUTIVE OFFICER) purchased 79,500 shares for an estimated $1,930,896
- MARK S. LIVINGSTON (CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 21,975 shares for an estimated $560,362.
- ALLISON SWARTZ (EVP, GC) has made 0 purchases and 4 sales selling 5,925 shares for an estimated $146,619.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PGNY Revenue
$PGNY had revenues of $313.3M in Q3 2025. This is an increase of 9.32% from the same period in the prior year.
You can track PGNY financials on Quiver Quantitative's PGNY stock page.
$PGNY Hedge Fund Activity
We have seen 158 institutional investors add shares of $PGNY stock to their portfolio, and 161 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 1,858,195 shares (-12.5%) from their portfolio in Q4 2025, for an estimated $47,718,447
- FMR LLC added 1,856,486 shares (+39.4%) to their portfolio in Q3 2025, for an estimated $39,951,578
- ALLIANZ ASSET MANAGEMENT GMBH added 841,365 shares (+4141.8%) to their portfolio in Q4 2025, for an estimated $21,606,253
- LOOMIS SAYLES & CO L P added 775,580 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,916,894
- D. E. SHAW & CO., INC. removed 717,922 shares (-42.7%) from their portfolio in Q3 2025, for an estimated $15,449,681
- BARCLAYS PLC added 696,447 shares (+79.2%) to their portfolio in Q3 2025, for an estimated $14,987,539
- CITADEL ADVISORS LLC added 594,506 shares (+181.6%) to their portfolio in Q3 2025, for an estimated $12,793,769
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PGNY Analyst Ratings
Wall Street analysts have issued reports on $PGNY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 01/20/2026
To track analyst ratings and price targets for $PGNY, check out Quiver Quantitative's $PGNY forecast page.
$PGNY Price Targets
Multiple analysts have issued price targets for $PGNY recently. We have seen 6 analysts offer price targets for $PGNY in the last 6 months, with a median target of $27.5.
Here are some recent targets:
- Constantine Davides from Citizens set a target price of $30.0 on 01/20/2026
- Scott Schoenhaus from Keybanc set a target price of $32.0 on 01/08/2026
- Glen Santangelo from Barclays set a target price of $29.0 on 12/09/2025
- Richard Close from Canaccord Genuity set a target price of $26.0 on 11/17/2025
- Lisa Gill from JP Morgan set a target price of $26.0 on 11/11/2025
Full Release
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026.
The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.
Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode.
An audio replay of the call will be available through Thursday, March 5, 2026, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.
A live webcast and archive of the call will be available from the Events and Presentations section of the Company’s website at http://investors.progyny.com .
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart
[email protected]
Media:
Alexis Ford
[email protected]
